Wang Pan, Zhao Honglin, Ren Fan, Zhao Qingchun, Shi Ruifeng, Liu Xingyu, Liu Jinghao, Li Yongwen, Li Ying, Liu Hongyu, Chen Jun
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin Lung Cancer Institute, Tianjin Key Laboratory of lung Cancer Metastasis and Tumor Microenvironment, Tianjin 300052, China.
Zhongguo Fei Ai Za Zhi. 2020 Feb 20;23(2):91-100. doi: 10.3779/j.issn.1009-3419.2020.02.04.
Epigenetic modification is closely related to the occurrence and development of tumors. It mainly regulates gene function and expression level through DNA methylation, histone modification, regulation of non-coding RNA and chromatin structure reconstruction. At present, epigenetic drugs have been gradually applied to the treatment of malignant tumors. Common drug types include: DNA methyltransferase inhibitors and histone deacetylase inhibitors. However, these drugs still have many shortcomings and a wide range of clinical applications need further research. Encouragingly, the epigenetic drugs in combination with various anti-tumor drugs have shown great application potential. In this paper, we summarized the development mechanism of epigenetics in malignant tumors and the progress of related drugs.
表观遗传修饰与肿瘤的发生发展密切相关。它主要通过DNA甲基化、组蛋白修饰、非编码RNA调控和染色质结构重建来调节基因功能和表达水平。目前，表观遗传药物已逐渐应用于恶性肿瘤的治疗。常见的药物类型包括：DNA甲基转移酶抑制剂和组蛋白去乙酰化酶抑制剂。然而，这些药物仍存在许多缺点，广泛的临床应用还需要进一步研究。令人鼓舞的是，表观遗传药物与各种抗肿瘤药物联合使用已显示出巨大的应用潜力。在本文中，我们总结了表观遗传学在恶性肿瘤中的发展机制及相关药物的研究进展。
